Online inquiry

IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11560MR)

This product GTTS-WQ11560MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11560MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12152MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MORAb-004
GTTS-WQ10522MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ9662MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ12298MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ11694MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ4515MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ10149MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ3323MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AT-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW